West Pharmaceutical Services Inc (WST, Financial) experienced a daily loss of 2.49%, contrasting with a modest 3-month gain of 0.55%. With an Earnings Per Share (EPS) of 7.58, a key question arises: Is the stock fairly valued? This article delves into the valuation of West Pharmaceutical Services, encouraging investors to explore the detailed analysis that follows.
Company Introduction
West Pharmaceutical Services, based in Pennsylvania, is a pivotal supplier in the pharmaceutical, biotechnology, and generic drug industries, specializing in elastomer-based packaging components and auto-injectors for injectable drugs. The company operates primarily through two segments: proprietary products, which generate about 80% of its revenue, and contract-manufactured products. Notably, West Pharmaceutical Services garners approximately 55% of its revenue from international markets and 45% from the United States. With a current stock price of $346.78 and a market cap of $25.30 billion, the GF Value estimates the fair value at $373.22, suggesting that the stock might be fairly valued.
Summarize GF Value
The GF Value is a proprietary measure calculated based on historical trading multiples, a GuruFocus adjustment factor from past performance, and future business performance estimates. This intrinsic value suggests that West Pharmaceutical Services (WST, Financial) is fairly valued. The GF Value line indicates that if a stock trades significantly above this line, it is considered overvalued and might yield poorer returns in the future. Conversely, trading below the line suggests a potential for higher returns.
Financial Strength
Investing in companies with robust financial strength reduces the risk of permanent capital loss. West Pharmaceutical Services boasts a cash-to-debt ratio of 1.96, surpassing 50.58% of its peers in the Medical Devices & Instruments industry. This strong financial position is reflected in the company's financial strength rating of 9 out of 10 by GuruFocus.
Profitability and Growth
West Pharmaceutical Services has maintained profitability over the past decade, with an impressive operating margin of 22.71%, ranking better than 90.34% of its industry peers. The company's 3-year average annual revenue growth rate is 11.4%, indicating solid growth prospects.
ROIC vs WACC
Comparing the Return on Invested Capital (ROIC) and the Weighted Average Cost of Capital (WACC) provides insight into financial efficiency. West Pharmaceutical Services has an ROIC of 21.53, significantly higher than its WACC of 11.63, suggesting efficient value creation.
Conclusion
West Pharmaceutical Services (WST, Financial) appears to be fairly valued based on its current market performance and intrinsic valuation metrics. The company's strong financial health and robust profitability underscore its potential for sustained growth. Interested investors can further explore West Pharmaceutical Services' 30-Year Financials here.
To discover high-quality companies that may deliver above-average returns, please check out the GuruFocus High Quality Low Capex Screener.
This article, generated by GuruFocus, is designed to provide general insights and is not tailored financial advice. Our commentary is rooted in historical data and analyst projections, utilizing an impartial methodology, and is not intended to serve as specific investment guidance. It does not formulate a recommendation to purchase or divest any stock and does not consider individual investment objectives or financial circumstances. Our objective is to deliver long-term, fundamental data-driven analysis. Be aware that our analysis might not incorporate the most recent, price-sensitive company announcements or qualitative information. GuruFocus holds no position in the stocks mentioned herein.
